Prevention, treatment of invasive fungal disease in allogeneic stem-cell transplantation recipients

Share this content:

the ONA take:

A team of researchers from Shanghai, China, hypothesized that prophylactic therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases invasive fungal disease (IFD) in patients undergoing allogeneic hematopoietic stem-cell transplantation (alloHSCT).

They compared once-daily subcutaneous GM-CSF (5 to 7 µg/kg per day), granulocyte colony-stimulating factor (G-CSF; 5 to 7 µg/kg per day), or a combination of G-CSF and GM-CSF (2 to 3 µg/kg per day each).

They randomly assigned 206 patients undergoing alloHSCT to one of the three treatments, which were started on day 5 after transplantation. Treatment was continued until the absolute neutrophil count was ≥1.5x109/L for 2 consecutive days.

The results showed no significant difference in 100-day incidences of proven and probable IFD among the three groups. In the GM-CSF and G-CSF+GM-CSF groups, 100-day cumulative mortality after transplantation and 100-day transplantation-related mortality were lower than in the G-CSF group.

IFD-related mortality was also lower in the GM-CSF and G-CSF+GM-CSF groups after 600 days follow-up, compared with the G-CSF group.

The researchers conclude that prophylactic GM-CSF improves 100-day transplantation-related mortality, 100-day cumulative mortality, and 600-day IFD-related mortality in recipients of alloHSCT, compared with G-CSF.

Mutated genes in leukemia can reprogram blood stem cells, affecting blood cell production.
Prophylactic therapy with granulocyte-macrophage colony-stimulating factor may decrease invasive fungal disease.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs